口服地塞米松辅助治疗非ICU住院社区获得性肺炎的随机临床试验
在这项荷兰四家教学医院开展的多中心、分层随机、双盲、安慰剂对照试验中,401例免疫功能正常的社区获得性肺炎(CAP)成人住院患者按1:1随机接受口服地塞米松6 mg每日一次共4天或安慰剂。地塞米松组中位住院时间(LOS)为4.5天(95%CI 4.0-5.0),短于安慰剂组的5.0天(95%CI 4.6-5.4;p=0.033),ICU入住率更低(3%对7%;p=0.030),但再入院率有升高趋势(10%对5%;p=0.051)、高血糖更常见(7%对1%;p=0.001),30天死亡率无差异。
要点
- 口服地塞米松6 mg每日一次共4天可缩短CAP住院患者的中位LOS。
- 地塞米松组ICU入住率更低,但再入院率有升高趋势、高血糖更常见。
- 按CAP严重程度分层的两个亚组内,LOS差异均无统计学意义。
核心结论
- 口服地塞米松可缩短CAP成人住院患者的LOS并降低ICU入住率,但哪些患者获益风险比最佳仍不明确。
研究设计与样本
- 多中心、分层随机、双盲、安慰剂对照试验,在荷兰四家教学医院开展。
- 纳入免疫功能正常的CAP成人住院患者,按1:1随机分组(区组大小为4)。
- 随机化按CAP严重程度分层(肺炎严重指数I-III级与IV-V级)。
- 干预为口服地塞米松6 mg每日一次或安慰剂,共4天。
主要发现
- 地塞米松组中位LOS为4.5天(95%CI 4.0-5.0),安慰剂组为5.0天(95%CI 4.6-5.4),p=0.033。
- 两个CAP严重程度亚组内,治疗组间LOS差异均无统计学意义。
- ICU入住率地塞米松组为5例(3%),安慰剂组为14例(7%),p=0.030。
- 30天死亡率两组无差异。
- 再入院率地塞米松组20例(10%)、安慰剂组9例(5%),p=0.051;高血糖14例(7%)对1例(1%),p=0.001。
关键数值与推荐
- 口服地塞米松剂量为6 mg每日一次,疗程4天。
临床怎么用
- 对非ICU住院的CAP成人可考虑口服地塞米松6 mg每日一次共4天以缩短住院时间。
- 用药时需关注高血糖和再入院风险,并个体化评估获益风险比。
局限性
- 原文摘要未报告纳入人群的具体特征与合并症分布细节。
- 各CAP严重程度亚组内LOS差异无统计学意义,获益人群尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjunctive intravenous corticosteroid treatment has been shown to reduce length of stay (LOS) in adults hospitalised with community-acquired pneumonia (CAP). We aimed to assess the effect of oral dexamethasone on LOS and whether this effect is disease severity dependent. METHODS: In this multicentre, stratified randomised, double-blind, placebo-controlled trial, immunocompetent adults with CAP were randomly assigned (1:1 ratio) to receive oral dexamethasone (6 mg once daily) or placebo for 4 days in four teaching hospitals in the Netherlands. Randomisation (blocks of four) was stratified by CAP severity (pneumonia severity index class I-III and IV-V). The primary outcome was LOS. RESULTS: Between December 2012 and November 2018, 401 patients were randomised to receive dexamethasone (n=203) or placebo (n=198). Median LOS was shorter in the dexamethasone group (4.5 days, 95% CI 4.0-5.0 days) than in the placebo group (5.0 days, 95% CI 4.6-5.4 days; p=0.033). Within both CAP severity subgroups, differences in LOS between treatment groups were not statistically significant. The secondary ICU admission rate was lower in the dexamethasone arm (5 (3%) versus 14 (7%); p=0.030); 30-day mortality did not differ between groups. In the dexamethasone group the rate of hospital readmission tended to be higher (20 (10%) versus 9 (5%); p=0.051) and hyperglycaemia (14 (7%) versus 1 (1%); p=0.001) was more prevalent. CONCLUSION: Oral dexamethasone reduced LOS and ICU admission rate in adults hospitalised with CAP. It remains unclear for which patients the risk-benefit ratio is optimal.
引用
- Wittermans E, Vestjens SMT, Spoorenberg SMC, et al. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial. Eur Respir J. 2021. PMID: 33446608. doi:10.1183/13993003.02535-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。